<DOC>
	<DOCNO>NCT02496546</DOCNO>
	<brief_summary>The aim trial ass efficacy LEO 32731 cream 20 mg/g compare LEO 32731 cream vehicle adult mild moderate AD 3 week treatment .</brief_summary>
	<brief_title>An Explorative Trial Evaluating Effect LEO 32731 Cream Adults With Mild Moderate Atopic Dermatitis ( AD )</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Following verbal write information trial , subject must provide informed consent document signing Informed Consent Form ( ICF ) prior trial related procedure carry Subject Atopic Dermatitis ( AD ) define Hanifin Rajka criterion mild moderate disease severity ( IGA 2 3 ) assess dermatologically train investigator ( confirm board certify dermatologist visit 1 ) Two symmetrically locate comparable Entire Treatment Areas ( ETAs ) 20 50 cm2 , i.e . body region ( leave right part ) size ( complete AD lesion part AD lesion ) ; Total Sign Score ( TSS ) least 5 ETAs ; difference TSS great 2 two ETAs ; sign score erythema ≥ 2 ETAs ; difference Investigator´s Treatment Area assessment disease severity great 1 2 ETAs Any condition treatment area opinion investigator could interfere clinical assessment , e.g . acne , infection , rash ( Atopic Dermatitis ) , sunburn , hyper hypopigmentation , scar</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>